Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and ...

Certain genetic mutations can boost your risk of breast cancer. Here’s what experts say you need to know when making the decision to get tested. Possible anomalies in a breast cancer screening are ...

Integrating HER2-directed therapies into NSCLC decision-making requires adapting protocols and ensuring timely updates as new therapies emerge. Streamlined processes and enhanced communication among ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

I was 18 when my mom was diagnosed with breast cancer. It altered the trajectory of my second year at college and changed how I viewed my mom, whom I naively thought was exempt from harm. She knew ...

We offer targeted detection of a previously characterized mutation within the family. From a fresh EDTA blood sample, DNA is extracted directly and the target region is amplified and directly ...

Dr. Angie DeMichele and Dr. Lynn Henry present the latest rapid recommendation impacting two ASCO guidelines. This update focuses on testing for ESR1 mutations in patients with hormone ...

Gila Pfeffer is a humor writer who splits her time between NYC and London. The following is an adapted excerpt from her memoir, "Nearly Departed: Adventures in Loss, Cancer, and Other Inconveniences." ...